Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial

October 2021 in “ Clinical, Cosmetic and Investigational Dermatology ”

Janet DuBois, Suzanne Bruce, Daniel Stewart, Steven Kempers, Christy Harutunian, Terry Boodhoo, Amy Weitzenfeld, Joan-En Chang-Lin

setipiprant CRTH2 antagonist androgenetic alopecia finasteride placebo AGA Propecia

From the encyclopedia

Setipiprant →

Finasteride →

Frontline, gold standard treatment for combatting androgenic alopecia

Studysummary This study found that oral setipiprant was safe but did not improve scalp hair growth compared to placebo in men with androgenetic alopecia.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study evaluated the efficacy and safety of setipiprant, a CRTH2 antagonist, for treating androgenetic alopecia (AGA) in 169 men over 24 weeks. Results showed no significant improvement in hair growth with setipiprant compared to placebo, although it was well tolerated. Finasteride, used as an unblinded reference, showed greater numerical improvements in hair count but was not formally compared. The study concluded that setipiprant did not significantly enhance hair growth in men with AGA.

View this study on dovepress.com →

Discuss this study in the Community →

Research cited in this study

17 / 17 results

research Safety Concerns When Using Novel Medications to Treat Alopecia

23 citations , October 2018 in “Expert Opinion on Drug Safety”

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

research Evidence-Based Guideline for the Treatment of Androgenetic Alopecia in Women and Men – Short Version

145 citations , November 2017 in “Journal of The European Academy of Dermatology and Venereology”

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

research Multi-Therapies in Androgenetic Alopecia: Review and Clinical Experiences

55 citations , July 2016 in “Dermatologic Therapy”

This article reviews treatment options for androgenetic alopecia and suggests that therapy should be personalized and targeted at various pathophysiological aspects, but reports no new clinical findings.

research Does Prostaglandin D2 Hold the Cure to Male Pattern Baldness?

57 citations , February 2014 in “Experimental Dermatology”

This review discusses the role of Prostaglandin D2 and its synthase in androgenetic alopecia but reports no new clinical findings, suggesting pathways for future therapeutic development.

A Randomized, Active- and Placebo-Controlled Study of the Efficacy and Safety of Different Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects with Androgenetic Alopecia

research A Randomized, Active- and Placebo-Controlled Study of the Efficacy and Safety of Different Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects with Androgenetic Alopecia

97 citations , January 2014 in “Journal of The American Academy of Dermatology”

This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.

research Prostaglandin D2 Inhibits Wound-Induced Hair Follicle Neogenesis Through the Receptor Gpr44

68 citations , November 2012 in “Journal of Investigative Dermatology”

This study found that PGD2 inhibits hair follicle regeneration in mice through the Gpr44 receptor, suggesting that blocking PGD2 or Gpr44 may enhance skin regeneration after wounds.

research The Prostamide-Related Glaucoma Therapy, Bimatoprost, Offers a Novel Approach for Treating Scalp Alopecias

53 citations , October 2012 in “The FASEB Journal”

This study found that bimatoprost stimulated hair growth in both human scalp follicle cultures and mouse pelage in vivo, suggesting it might offer a promising treatment for scalp alopecias.

research Prostaglandin D2 Inhibits Hair Growth and Is Elevated in Bald Scalp of Men with Androgenetic Alopecia

205 citations , March 2012 in “Science Translational Medicine”

PGD2 stops hair growth and is higher in bald men with AGA.

research Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia

152 citations , October 2010 in “Archives of Dermatology”

This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.

research Male Androgenetic Alopecia

100 citations , April 2010 in “Expert Opinion on Pharmacotherapy”

This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.

The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride

research The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride

215 citations , November 2006 in “Journal of The American Academy of Dermatology”

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

research Psychological Effect, Pathophysiology, and Management of Androgenetic Alopecia in Men

112 citations , October 2005 in “Mayo Clinic Proceedings”

This article reviews the clinical, psychological, and management aspects of androgenetic alopecia in men, stating that it can be effectively managed by generalist clinicians with pharmacotherapy and surgical advancements.

A Randomized Clinical Trial of 5% Topical Minoxidil Versus 2% Topical Minoxidil and Placebo in the Treatment of Androgenetic Alopecia in Men

research A Randomized Clinical Trial of 5% Topical Minoxidil Versus 2% Topical Minoxidil and Placebo in the Treatment of Androgenetic Alopecia in Men

269 citations , August 2002 in “Journal of The American Academy of Dermatology”

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

research Prostaglandin-Induced Hair Growth

162 citations , August 2002 in “Survey of Ophthalmology”

This study found that latanoprost induces significant growth and pigmentation of lashes and ancillary hairs, with effects mirroring both brief and chronic treatments observed in patients and animal models.

research Clinical Dose Ranging Studies with Finasteride, a Type 2 5α-Reductase Inhibitor, in Men with Male Pattern Hair Loss

46 citations , October 1999 in “Journal of The American Academy of Dermatology”

This study found that finasteride at 1 mg/day was the most effective dose for treating male pattern hair loss, with similar efficacy to 5 mg/day and better results than lower doses.

research Finasteride, a Type 2 5α-Reductase Inhibitor, in the Treatment of Men with Androgenetic Alopecia

32 citations , April 1999 in “Expert Opinion on Investigational Drugs”

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

research The Psychological Effects of Androgenetic Alopecia in Men

192 citations , June 1992 in “Journal of The American Academy of Dermatology”

Hair loss can cause low self-esteem, anxiety, and depression in men.